Exabis Library
Welcome to the e-CCO Library!
P613: Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-alpha inhibitors and conventional immunosuppressants
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P613: Predictors of treatment persistence in ulcerative colitis patients treated with golimumab: A multicentre cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P613: Social Media Analytics for Inflammatory Bowel Disease – What Are We Missing?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P613: Switch from intravenous to subcutaneous maintenance infliximab in real world IBD cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P613: Tacrolimus as rescue therapy for steroid-dependent/steroid refractory ulcerative colitis: experience from tertiary referral centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P614 Micro-fragmented autologous adipose tissue injection for fistula-in-ano (MAATIFA) in patients with Crohn’s disease: A prospective observational study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P614: A strategy to solve complexity of physician diagnosis using a mixture of Patient Reports and Provider Reports: A Case Study of Crohn’s Disease Phenotypes
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P614: Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P614: Pregnancy outcomes in women with IBD treated with biosimilar infliximab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P614: Proactive infliximab is superior to either conventional infliximab and vedolizumab in Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P614: Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P614: The utility as a biomarker of faecal calprotectin for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis treatment in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P615 Safety of vedolizumab in the treatment of IBD in a single tertiary centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P615: Does smoking really influence the development and the outcomes of Inflammatory Bowel Disease in Asian population? Results from the Taiwanese patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P615: Efficacy of vedolizumab in patients with Crohn's disease may differ depending on the disease location: The UCLH experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P615: Improving IBD monitoring by understanding preanalytical faecal calprotectin variability
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P615: Rescue infliximab for acute severe colitis: a single-centre experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P615: The safety and efficacy of ustekinumab combined with sphincter-preserving surgery for perianal fistulizing Crohn's disease:a single-center retrospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P615: The unfinished symphony: golimumab is efficient in patients with refractory Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P616 IBD reference and biosimilar adalimumab CroSS over study (iBaSS): design considerations and methodology
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM